NASDAQ
1.30USD
-0.01 (-0.76%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
24.9M
P/E
—
EPS
—
Beta
0.75
52W range
0.55-10
Day range
1.30–1.30
Open
1.30
Prev close
1.31
Volume
53.5K
Avg volume
1.5M
Dividend
0.00
IPO
2021-12-15
https://www.globenewswire.com/news-release/2026/07/23/3331896/0/en/Genenta-backed-S%C3%B2phia-High-Tech-Brings-Aerospace-Precision-Inside-a-Nuclear-Fusion-Reactor-with-ROMAN-a-Robotic-Arm.html · 7/23/2026+0.80
https://www.globenewswire.com/news-release/2026/07/22/3331105/0/en/Genenta-Backed-S%C3%B2phia-High-Tech-Reports-Fiscal-Year-2025-Results.html · 7/22/2026+0.60
https://www.globenewswire.com/news-release/2025/10/27/3174282/0/en/Genenta-Announces-Pricing-of-15-0-Million-Registered-Direct-Offering-of-American-Depositary-Shares.html · 10/27/2025-0.20
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
